BACKGROUND: End-stage renal disease and its treatment are associated with sleep disturbances such as deterioration of the circadian sleep-wake pattern. Melatonin rhythm, which has an important role in this pattern, is disturbed. The nocturnal melatonin surge is absent in this population. Whether nocturnal in-center hemodialysis changes melatonin and sleep-wake rhythms is unknown. STUDY DESIGN: A nonrandomized uncontrolled trial. Patients served as their own controls. SETTING & PARTICIPANTS: Thirteen daytime hemodialysis patients (median age, 58 years; 5 women) from our hospital receiving conventional daytime hemodialysis 3 times weekly for 3 to 4 hours each session. INTERVENTIONS: Six months of treatment with nocturnal in-center dialysis 4 nights/wk with 8-hour sessions. OUTCOMES & MEASUREMENTS: At baseline, while still on conventional hemodialysis therapy, polysomnography was performed, sleep questionnaires were filled out, and melatonin concentration in saliva was obtained. After 6 months of in-center nocturnal hemodialysis, all measurements were repeated. RESULTS: After 6 months of in-center nocturnal hemodialysis, polysomnography showed significant improvements in sleep efficiency (P = 0.05) and stage 3/4 sleep (P = 0.03) in comparison to t = 0. Trends in improvement of rapid-eye-movement sleep, awake time, and oxygen saturation were seen after 6 months of in-center nocturnal hemodialysis therapy. Sleep questionnaires showed a trend in improved sleep quality and daytime function. Patients were less exhausted during the daytime. The nocturnal melatonin surge was partially restored. LIMITATIONS: Small sample size and a nonrandomized uncontrolled study design. CONCLUSIONS: Patients after 6 months of in-center nocturnal hemodialysis had significant improvements in subjective and objective sleep parameters and partially restored nocturnal melatonin rhythm.
BACKGROUND: End-stage renal disease and its treatment are associated with sleep disturbances such as deterioration of the circadian sleep-wake pattern. Melatonin rhythm, which has an important role in this pattern, is disturbed. The nocturnal melatonin surge is absent in this population. Whether nocturnal in-center hemodialysis changes melatonin and sleep-wake rhythms is unknown. STUDY DESIGN: A nonrandomized uncontrolled trial. Patients served as their own controls. SETTING & PARTICIPANTS: Thirteen daytime hemodialysis patients (median age, 58 years; 5 women) from our hospital receiving conventional daytime hemodialysis 3 times weekly for 3 to 4 hours each session. INTERVENTIONS: Six months of treatment with nocturnal in-center dialysis 4 nights/wk with 8-hour sessions. OUTCOMES & MEASUREMENTS: At baseline, while still on conventional hemodialysis therapy, polysomnography was performed, sleep questionnaires were filled out, and melatonin concentration in saliva was obtained. After 6 months of in-center nocturnal hemodialysis, all measurements were repeated. RESULTS: After 6 months of in-center nocturnal hemodialysis, polysomnography showed significant improvements in sleep efficiency (P = 0.05) and stage 3/4 sleep (P = 0.03) in comparison to t = 0. Trends in improvement of rapid-eye-movement sleep, awake time, and oxygen saturation were seen after 6 months of in-center nocturnal hemodialysis therapy. Sleep questionnaires showed a trend in improved sleep quality and daytime function. Patients were less exhausted during the daytime. The nocturnal melatonin surge was partially restored. LIMITATIONS: Small sample size and a nonrandomized uncontrolled study design. CONCLUSIONS:Patients after 6 months of in-center nocturnal hemodialysis had significant improvements in subjective and objective sleep parameters and partially restored nocturnal melatonin rhythm.
Authors: Eduardo Lacson; Jianglin Xu; Rita S Suri; Gihad Nesrallah; Robert Lindsay; Amit X Garg; Keith Lester; Norma Ofsthun; Michael Lazarus; Raymond M Hakim Journal: J Am Soc Nephrol Date: 2012-02-23 Impact factor: 10.121
Authors: Marije Russcher; Birgit C P Koch; J Elsbeth Nagtegaal; Frans J van Ittersum; Pieternel C M Pasker-de Jong; E Chris Hagen; Wim Th van Dorp; Bas Gabreëls; Thierry X Wildbergh; Monique M L van der Westerlaken; Carlo A J M Gaillard; Piet M Ter Wee Journal: Br J Clin Pharmacol Date: 2013-11 Impact factor: 4.335
Authors: Darren R Churchward; Matthew P M Graham-Brown; Robert Preston; Warren Pickering; Gerry P McCann; James O Burton Journal: BMJ Open Date: 2016-09-08 Impact factor: 2.692